Mosapramine
Clinical data | |
---|---|
Trade names | Cremin (クレミン, JP) |
AHFS/Drugs.com | International Drug Names |
Routes of administration | Oral (tablets, oral solution) |
ATC code | |
Legal status | |
Legal status |
|
Identifiers | |
IUPAC name
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG |
|
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C28H35ClN4O |
Molar mass | 479.07 g·mol−1 |
3D model (JSmol) | |
SMILES
| |
InChI
| |
(verify) |
Mosapramine (Cremin) is an atypical antipsychotic used in Japan.[1] It is a potent dopamine antagonist with high affinity to the D2, D3, and D4 receptors,[2] and with moderate affinity for the 5-HT2 receptors.[3]
See also
References
- ↑ Takahashi N, Terao T, Oga T, Okada M (1999). "Comparison of risperidone and mosapramine addition to neuroleptic treatment in chronic schizophrenia". Neuropsychobiology. 39 (2): 81–5. doi:10.1159/000026565. PMID 10072664. S2CID 6554048.
- ↑ Futamura T, Ohashi Y, Yano K, Takahashi Y, Haga K, Fukuda T (May 1996). "[The affinities of mosapramine for the dopamine receptor subtypes in human cell lines expressing D2, D3 and D4 receptors]". Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica. 107 (5): 247–53. doi:10.1254/fpj.107.247. PMID 8690306.
- ↑ Sumiyoshi T, Suzuki K, Sakamoto H, Yamaguchi N, Mori H, Shiba K, Yokogawa K (February 1995). "Atypicality of several antipsychotics on the basis of in vivo dopamine-D2 and serotonin-5HT2 receptor occupancy". Neuropsychopharmacology. 12 (1): 57–64. doi:10.1016/0893-133X(94)00064-7. PMID 7766287.
Typical |
|
---|---|
Disputed | |
Atypical |
|
Others |
|
|
Classes |
|
---|---|
Antidepressants (TCAs and TeCAs) |
|
Antihistamines |
|
Antipsychotics |
|
Anticonvulsants | |
Others |
|
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.